MLYS insider trading
HealthcareMineralys Therapeutics, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About Mineralys Therapeutics, Inc.
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. The company's clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea. It has initiated a Phase 2 trial for lorundrostat in hypertensive patients with stage 2 to 3b chronic kidney disease and a pivotal clinical program of lorundrostat for the treatment of uncontrolled or resistant hypertension. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. Mineralys Therapeutics, Inc. was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
Company website: mineralystx.com
MLYS insider activity at a glance
FilingIQ has scored 288 insider transactions for MLYS since Feb 14, 2023. The most recent filing in our index is dated May 13, 2026.
Across the full history, 19 open-market purchases
and 105 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on MLYS insider trades is 60.9/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest MLYS Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
13F funds holding MLYS
Frequently asked
- How many insider trades does FilingIQ track for MLYS?
- FilingIQ tracks 288 Form 4 insider transactions for MLYS (Mineralys Therapeutics, Inc.), covering filings from Feb 14, 2023 onwards. 77 of those were filed in the last 90 days.
- Are MLYS insiders net buyers or net sellers?
- Across the full Form 4 history for MLYS, 19 transactions (7%) were open-market purchases and 105 (36%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does MLYS insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is MLYS in?
- Mineralys Therapeutics, Inc. (MLYS) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $2.20B.
Methodology & sources
Every MLYS insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.